share_log

Benchmark Reiterates Speculative Buy on Anebulo Pharmaceuticals, Maintains $8 Price Target

Benchmark Reiterates Speculative Buy on Anebulo Pharmaceuticals, Maintains $8 Price Target

基準重申對Anebulo Pharmicals的投機性買盤,維持8美元的目標股價
Benzinga ·  2023/10/03 11:52

Benchmark analyst Robert Wasserman reiterates Anebulo Pharmaceuticals (NASDAQ:ANEB) with a Speculative Buy and maintains $8 price target.

基準分析師羅伯特·沃瑟曼重申安尼爾製藥(納斯達克:ANEB)的投機性買入,並維持8美元的目標價。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論